The company said, “Revenue for the full year 2025 is expected to be in the range of $45.5 million to $47.5 million, representing growth of 67% to 75% over 2024.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARL:
- CVS Health upgraded, Occidental downgraded: Wall Street’s top analyst calls
- Carlsmed initiated with a Buy at Truist
- Buy Rating for Carlsmed: Innovative Aprevo Technology and Strong Growth Projections Justify Premium Valuation
- Carlsmed initiated with a Buy at BofA
- Carlsmed initiated with a Buy at BTIG